BioSig Technologies, Inc Closes $17.5 Million Common Stock Offering
29 juin 2020 08h18 HE
|
BioSig Technologies, Inc.
Westport, CT, June 29, 2020 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”) and its majority-owned subsidiary, ViralClear Pharmaceuticals, Inc., today...
BioSig Technologies, Inc. Announces $17.5 Million Common Stock Only Registered Direct Offering
24 juin 2020 09h20 HE
|
BioSig Technologies, Inc.
Westport, CT, June 24, 2020 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”) today announced that it has entered into definitive agreements with several...
ViralClear Partners with Catalent on Potential Treatment for COVID-19
22 juin 2020 14h30 HE
|
BioSig Technologies, Inc.
Westport, CT, June 22, 2020 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”) and its subsidiary, ViralClear Pharmaceuticals, Inc., today announced that it has...
ViralClear Opens Enrollment with First Patient Dosing in Phase II Human Trial of Anti-Viral MMPD Oral Solution for Treatment of COVID-19
17 juin 2020 07h55 HE
|
BioSig Technologies, Inc.
Westport, CT, June 17, 2020 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”) and its subsidiary, ViralClear Pharmaceuticals, Inc., today announced that it has...
Reminder - BioSig Subsidiary, ViralClear to Host Conference Call on June 9th to Discuss Upcoming and Recent Developments for Phase II Human Clinical Trials of its Broad-Spectrum Oral Anti-Viral Candidate for Treatment of COVID-19
08 juin 2020 15h02 HE
|
BioSig Technologies, Inc.
Westport, CT, June 08, 2020 (GLOBE NEWSWIRE) -- Company to provide updates on the initiation of human trials for treatment of adult hospitalized patients with COVID-19Phase II clinical trial will be...
ViralClear adds St. David's HealthCare in Austin, Texas, to its Planned Phase II trial for its Broad-Spectrum Oral Anti-Viral Candidate for COVID-19
05 juin 2020 09h10 HE
|
BioSig Technologies, Inc.
Westport, CT, June 05, 2020 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”) and its majority owned subsidiary, ViralClear Pharmaceuticals, Inc., today...
BioSig Technologies’s PURE EP System to be Presented in Heart Rhythm Society 2020 Science Sessions
04 juin 2020 09h25 HE
|
BioSig Technologies, Inc.
Westport, CT, June 04, 2020 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing a proprietary biomedical signal...
BioSig Technologies Expands Intellectual Property Portfolio
03 juin 2020 11h45 HE
|
BioSig Technologies, Inc.
Westport, CT, June 03, 2020 (GLOBE NEWSWIRE) -- U.S. Patent and Trademark Office awards Company additional patent for PURE EP™ System Five patent applications filed by ViralClear Pharmaceuticals,...
ViralClear to Host Conference Call on June 9th to Discuss Upcoming and Recent Developments for Phase II Human Clinical Trials of its Broad-Spectrum Oral Anti-viral Candidate for Treatment of COVID-19
01 juin 2020 10h42 HE
|
BioSig Technologies, Inc.
Westport, CT, June 01, 2020 (GLOBE NEWSWIRE) -- Company to provide updates on the initiation of human trials for treatment of adult hospitalized patients with COVID-19Phase II clinical trial will be...
Michael R. Dougherty Joins the Board of ViralClear Pharmaceuticals, a majority-owned subsidiary of BioSig Technologies, Inc.
28 mai 2020 08h40 HE
|
BioSig Technologies, Inc.
Westport, CT, May 28, 2020 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”) today appointed Mr. Michael R. Dougherty to the Board of Directors of its...